Regulator delays decision on Amarin's Vascepa

Amarin (AMRN) says the FDA's Division of Metabolism and Endocrinology Products has delayed a decision on the reinstatement of the ANCHOR SPA.

There is currently "no definitive date for [a] planned response."

Although the company says that "based on dialogue with DMEP, [it] does not expect the delay to be for a significant period of time ... there can be no assurance that AMRN will be successful." (PR)

The shares, which had run up in the regular session, are down 9% AH.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs